


Message from the CEO, Dr. Randolph Kerschbaumer

As 2022 will be a transformative year for OncoOne, we want to provide an overview of our recent achievements and upcoming events which highlight the momentum the company is building. We continue to make rapid progress in our pipeline development efforts and have

gained important validation from the scientific community on the potential of oxMIF-targeted therapeutics. As the pioneers in drugging the macrophage migration inhibitory factor, we appreciate the opportunity to re-connect with you to provide more details on our approach.

First Quarter 2022 Highlights

1. **Successfully identified** two lead development programs, **ON203** for solid tumors and **ON104** for immunology, with plans to initiate phase I studies for both in 2023
2. Submitted to **U.S. Food and Drug Administration** for preclinical & clinical development guidance of ON203
3. In preparation of upcoming Phase I clinical study, secured a **partnership** with **Harvard's Massachusetts General Hospital Cancer Center** to lead the first-in-human trial of ON203 in patients with solid tumors
4. The preclinical data poster, entitled, "Novel bioengineered monoclonal antibodies targeting oxidized macrophage migration inhibitory factor (oxMIF) as anti-cancer therapeutics and diagnostics", was accepted for presentation at the **American Association of Cancer Research (AACR) Annual Meeting** in New Orleans, USA
5. Welcomed the recognition from a recent article published in CellPress' *Structure* by several independent labs including Brown, UNC-Chapel Hill, and Scripps, **validating oxMIF through mass spectrometry as a distinct isoform of MIF**, referencing foundational research



(l to r) Brent M., Randolph K., and Alexander S. pose for a photo in front of the OncoOne poster presentation at the AACR Annual Meeting in New Orleans, USA, April 2022

Upcoming Events

Our **Chief Scientific Officer, Dr. Michael Thiele**, has been selected to give a scientific presentation at the **18th Protein Engineering & Cell Therapy Summit** (PEGS Boston Conference and Expo) on May 3, 2022. Michael and members of the OncoOne team will also present a poster at **Immuno-Oncology Summit Europe** in London, May 23-25, 2022.

Director of Preclinical and Project Lead Inflammation, Dr. Christine Landlinger will be giving a presentation at the **15th annual World Congress on Inflammation** in Rome, Italy in June 2022. Dr. Landlinger will present a scientific overview of ON104, a next-generation antibody targeting the oxidized macrophage migration inhibitory factor (oxMIF), in experimental models of glomerulonephritis and rheumatoid arthritis.

OncoOne's **Senior Scientist, Dr. Barbara Maurer** will be presenting a poster at the **European Association of Cancer Research (EACR) Congress 2022** in Sevilla and the **ESMO World Congress on Gastrointestinal Cancers** in Barcelona in June 2022.

OncoOne will be sharing invited corporate presentations at both **BioEquity Europe** in Milan, Italy, May 16-18th, and the **2022 BIO International Conference** in San Diego, California, June 13-16th.

Please Stay in Touch! @OncoOne

The Founders of OncoOne discovered and named the oxidized isoform of MIF and have developed optimized monoclonal antibody-based therapies to treat a range of solid tumors and inflammation as both single-agents or in combination with standard of care regimens.

Utilizing their foundational knowledge of oxMIF and expertise in drug development, OncoOne presents a unique opportunity in overcoming the challenges of drugging the critical cytokine MIF and thereby accessing major markets with their ability to harness the therapeutic effects of this novel target.



OncoOne CEO, Randolph K. presenting a company overview at the BIO CEO and Investor Conference, February 2022

OncoOne is currently holding discussions for an upcoming Series B financing round which will advance ON203 through to phase II proof of concept and accelerate ON104 into clinic in 2023. We are also engaged in potential partnering opportunities based on our pipeline and expertise including securing a partner for the China market.

We look forward to hearing from you – please reach out for any request to brent.meadows@oncoone.com.